Editas Medicine (EDIT) Interest Expenses (2025)

Editas Medicine (EDIT) has reported Interest Expenses for 11 consecutive years, with $1.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Interest Expenses rose 587.19% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (down 65.56% YoY), while the FY2025 annual figure was $1.4 million, down 99.64% from the prior year.
• Interest Expenses declined to $1.4 million in Q4 2025 per EDIT's latest filing, from $2.4 million in the prior quarter.
• Across five years, Interest Expenses topped out at $4.0 billion in Q1 2022 and bottomed at -$7.7 million in Q4 2021.
• Historically, Interest Expenses has averaged $416.2 million across 5 years, with a median of $16.9 million in 2021.
• Annual changes were most pronounced in 2022 — Interest Expenses surged 9023.09% — and 2024, when it plunged 98.37%.
• Editas Medicine's Interest Expenses stood at -$7.7 million in 2021, then soared by 62.83% to -$2.9 million in 2022, then jumped by 215.89% to $3.3 million in 2023, then slumped by 93.89% to $203000.0 in 2024, then surged by 587.19% to $1.4 million in 2025.
• Business Quant data shows EDIT's Interest Expenses at $1.4 million in Q4 2025, $2.4 million in Q3 2025, and $2.5 million in Q2 2025.